Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent…
Biotechnology
US, Boston [HQ]
Ratios
11 Sheets · From 2023 to 2012Configuration
Margins, Growth Rates In %
| Ratio | 2012 | 2013 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | - - | 81.01 | 90.98 | 87.99 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | -2,156.21 | -774.52 | -238.52 | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | - - | -5,391.85 | -757.92 | -238.10 | |
|
EPS Growth
|
- - | -19.44 | - - | -134.85 | -63.87 | 5.91 | -54.81 | 20.00 | 53.72 | -156.20 | 8.83 | |
| EPS USD | -36.00 | -43.00 | -66.00 | -155.00 | -254.00 | -239.00 | -370.00 | -296.00 | -137.00 | -351.00 | -320.00 | |
| Return on Assets (ROA) | -95.81 | -117.84 | -29.71 | -209.68 | -22.22 | -28.46 | -43.63 | -69.88 | -20.64 | -47.87 | -55.50 | |
| Return on Equity (ROE) | 49.97 | 37.30 | -34.60 | -354.56 | -23.28 | -30.08 | -47.91 | -78.50 | -23.93 | -69.28 | -108.79 | |
| Return on Invested Capital (ROIC) | 49.99 | 37.33 | -29.74 | -355.01 | -23.10 | -33.72 | -49.08 | -78.56 | -57.95 | -68.03 | -108.13 | |
| Solvency | ||||||||||||
| Equity Ratio | -100 | -300 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | 9.53 | - - | - - | - - | 1.15 | 1.65 | 0.77 | 0.51 | 0.38 | |
| Debt/Equity | - - | - - | 11.10 | - - | - - | - - | 1.27 | 1.85 | 0.90 | 0.74 | 0.74 | |
| Debt/EBITDA | 64.93 | 34.37 | 346.16 | 25.39 | 112.07 | 63.18 | 40.23 | 71.59 | 33.34 | 71.47 | 34.92 | |
|
Debt/Capitalization
|
- - | - - | 9.99 | - - | - - | - - | 1.25 | 1.82 | 0.89 | 0.73 | 0.74 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | - - | - - | 1.09 | 1.51 | 0.68 | 0.47 | 0.29 | |
| Interest Debt per Share USD | - - | - - | 0.21 | - - | - - | - - | 0.10 | 0.07 | 0.05 | 0.14 | 0.26 | |
| Debt Growth | - - | - - | - - | - - | - - | - - | - - | -13.27 | -17.34 | -23.80 | -35.19 | |
| Liquidity | ||||||||||||
| Current Ratio | 753.60 | 592.78 | 672.96 | 236.21 | 2,242.13 | 1,904.65 | 1,238.50 | 1,009.60 | 710.13 | 889.84 | 558.43 | |
| Quick Ratio | 680.90 | 580.46 | 661.15 | 222.72 | 2,203.60 | 1,855.85 | 1,197.77 | 960.28 | 681.33 | 852.85 | 526.63 | |
| Cash Ratio | 470.26 | 240.65 | 661.15 | 138.24 | 509.46 | 364.76 | 255.13 | 560.49 | 136.43 | 320.72 | 108.84 | |
| Operating Cash Flow Ratio | -700 | -600 | -100 | -400 | -400 | -400 | -500 | -600 | -300 | -400 | -200 | |
| Turnover | ||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | 539.64 | 73.12 | 107.86 | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | 307.71 | 379.79 | 520.80 | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | 8.01 | 14.08 | 10.44 | 44.47 | 190.42 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | - - | - - | - - | 0.96 | 6.18 | 23.27 | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | - - | - - | 72.76 | 699.56 | 3,648.82 | |
| Coverage | ||||||||||||
| Interest Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | -3,444.66 | -1,327.07 | |
| Asset Coverage | - - | - - | - - | - - | - - | - - | 7,900 | 5,400 | 11,000 | 17,200 | 21,500 | |
| Cash Flow Coverage (CFGR) | - - | - - | -196.37 | - - | - - | - - | -3,449.97 | -3,952.69 | -5,723.36 | -8,921.19 | -10,806.11 | |
| EBITDA Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | -3,300 | -1,200 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -1.20 | -1.42 | -2.21 | -5.16 | -8.74 | -8.89 | -16.10 | -9.97 | -13.74 | -12.06 | -6.97 | |
|
Price/Earnings (P/E)
|
-8,317.98 | -7,036.76 | -4,532.51 | -1,939.88 | -1,143.81 | -1,125.23 | -621.18 | -1,003.54 | -727.88 | -829.01 | -1,435.60 | |
| Price/Earnings Growth (PEG) | - - | -361.89 | - - | -14.39 | -17.91 | 190.54 | -11.33 | 50.18 | 13.55 | -5.31 | 162.55 | |
|
Price/Book (P/B)
|
-4,156.24 | -2,624.52 | 1,568.34 | 6,877.96 | 266.30 | 338.42 | 297.58 | 787.80 | 174.21 | 574.34 | 1,561.76 | |
| Price/Tangible Book (P/TB) | -4,156.24 | -2,624.52 | 1,568.34 | 6,877.96 | 266.30 | 338.42 | 297.58 | 787.80 | 174.21 | 574.34 | 1,561.76 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | - - | - - | - - | 15,694.70 | 6,420.83 | 3,424.13 | |
|
Price/Cash Flow (P/CF)
|
-8,457.93 | -7,872.46 | -7,193.42 | -2,161.53 | -1,308.78 | -1,342.96 | -681.27 | -1,075.51 | -339.04 | -875.15 | -1,947.19 | |
| Price/Free CF (P/FCF) | -8,457.93 | -7,872.46 | -7,175.93 | -2,067.41 | -1,302.90 | -1,327.52 | -662.99 | -1,073.62 | -326.88 | -854.07 | -1,946.52 | |
| Price/Operating CF (P/OCF) | -8,457.93 | -7,872.46 | -7,193.42 | -2,161.53 | -1,308.78 | -1,342.96 | -681.27 | -1,075.51 | -339.04 | -875.15 | -1,947.19 |